The 6 analysts offering 12-month price forecasts for Ligand Pharmaceuticals Inc have a median target of 103.50, with a high estimate of 144.00 and a low estimate of 90.00. The median estimate represents a +77.26% increase from the last price of 58.39.
The current consensus among 6 polled investment analysts is to Buy stock in Ligand Pharmaceuticals Inc. This rating has held steady since June, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $0.83
Reporting Date Feb 21
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.